Details of the investment are not being disclosed.
Ionpath's MIBI (Multiplexed Ion Beam Imaging) technology is delivering on the promise of spatial proteomics by providing unprecedented insights for translational medicine researchers.
Through highly multiplexed, quantitative protein imaging with high sensitivity and true subcellular resolution down to 350 nm, MIBI technology delivers actionable insights of single cells in their complex tissue microenvironment with the throughput and reproducibility required for clinical studies.
Ionpath, Inc., is a pioneer in high-definition spatial proteomics, revolutionizing tissue imaging and analysis to accelerate medical discovery and improve human health.
Ionpath's MIBI (multiplexed ion beam imaging) platform breaks through the limitations of traditional immunohistochemistry, enabling a deeper understanding of the tissue microenvironment with highly multiplexed, quantitative single-cell analysis.
With MIBI technology and the expertise of world-class pathology and data science teams, Ionpath provides actionable insights for translational and clinical researchers at pharmaceutical, biotechnology, and research organizations in immuno-oncology, immunology, neuroscience, and infectious disease research.
Innovent Biologics names new Oncology CMO
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Precision Epigenomics partners with TruDiagnostic
Portage Biotech expands evaluation of strategic alternatives
Stamford Pharmaceuticals starts locally advanced basal cell carcinoma (laBCC) trial of SP-002
QST selects RayStation for advanced carbon ion therapy
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval
enGene Holdings names new senior vice president, Urologic Oncology and Clinical Development
CLS secures second order from NIH Clinical Center for Thermal Therapy System accessories